Compare PAYO & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYO | VERA |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 3.0B |
| IPO Year | 2021 | 2021 |
| Metric | PAYO | VERA |
|---|---|---|
| Price | $7.11 | $33.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $7.69 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 5.4M | 1.9M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $1,052,774,000.00 | N/A |
| Revenue This Year | $7.15 | N/A |
| Revenue Next Year | $10.28 | $472.48 |
| P/E Ratio | $142.20 | ★ N/A |
| Revenue Growth | ★ 7.68 | N/A |
| 52 Week Low | $4.08 | $21.15 |
| 52 Week High | $7.18 | $56.05 |
| Indicator | PAYO | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 56.61 | 51.39 |
| Support Level | $7.07 | $33.43 |
| Resistance Level | $7.16 | $42.77 |
| Average True Range (ATR) | 0.04 | 1.74 |
| MACD | -0.02 | 0.45 |
| Stochastic Oscillator | 60.71 | 75.98 |
Payoneer Global Inc is a financial technology company that enables small and medium-sized businesses (SMBs) to grow internationally through its diversified cross-border payments platform. It connects businesses, professionals, countries, and currencies, reducing the complexity of commerce and enabling customers to pay and get paid as easily as locally. The company offers a financial stack that includes cross-border AR/AP capabilities, funds management, working capital solutions, multicurrency accounts, and workforce management services. Its fully hosted platform provides multiple payment options with minimal integration, along with back-office functions and customer support. The company operates in Israel, the United States, and other countries.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.